Dr. Chen is Professor of Medicine, Chair of the Division of Circulatory Failure, Co-Director for the Biological Agents and Drug Innovation Program, Associate Director NIH T32 Training Program and Co-Director Cardiorenal Research Laboratory all at the Mayo Clinic.
Dr. Chen has been a pioneer in translating natriuretic peptide therapeutics from the bench to the bedside. His work has been continuously funded by the National Institutes of Health in heart failure. He provided scientific leadership to the First-in-Human study of MANP in human essential hypertension and is investigating MANP in human heart failure with preserved ejection fraction. He was the National Principal Investigator, leading a multicenter clinical trial performed within the NHLBI Heart Failure Clinical Research Network entitled: “The ROSE Study”. The Results of the study were presented as a late breaking clinical trial at the American Heart Association Scientific Session with simultaneous publication in JAMA.
Dr. Chen holds 7 patents for designer natriuretic peptides and serves on the Editorial Boards of Journal of the American College of Cardiology Heart Failure and the Journal of the Heart Failure Society of America. He is an elected member of the prestigious American Society of Clinical Investigation in 2012.